S&P 500 Rises as AI Stocks and Small Caps Rally on Strong Earnings Outlook 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korea Factory Activity Hits 18-Month High as Export Demand Surges 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Japan Finance Minister Defends PM Takaichi’s Remarks on Weak Yen Benefits 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
